Virtus ETF Advisers LLC Arcus Biosciences, Inc. Transaction History

Virtus ETF Advisers LLC

$206 Million
Q3 2024

A detailed history of Virtus ETF Advisers LLC transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Virtus ETF Advisers LLC holds 5,424 shares of RCUS stock, worth $87,217. This represents 0.04% of its overall portfolio holdings.

Number of Shares

5,424

Previous 5,325 1.86%

Holding current value

$87,217

Previous $81,000 1.23%

% of portfolio

0.04%

Previous 0.04%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$13.69 - $18.01 $1,355 - $1,782	99 Added 1.86%	5,424 $82,000
Q2 2024 Aug 14, 2024	BUY	$14.59 - $18.48 $6,040 - $7,650	414 Added 8.43%	5,325 $81,000
Q1 2024 May 15, 2024	SELL	$14.83 - $20.18 $5,042 - $6,861	-340 Reduced 6.47%	4,911 $92,000
Q4 2023 Feb 15, 2024	BUY	$13.43 - $19.63 $2,806 - $4,102	209 Added 4.15%	5,251 $100,000
Q3 2023 Nov 07, 2023	SELL	$17.62 - $23.54 $8,915 - $11,911	-506 Reduced 9.12%	5,042 $90,000
Q2 2023 Aug 14, 2023	BUY	$16.97 - $22.03 $43,069 - $55,912	2,538 Added 84.32%	5,548 $112,000
Q1 2023 May 15, 2023	SELL	$15.96 - $23.15 $18,449 - $26,761	-1,156 Reduced 27.75%	3,010 $54,000
Q4 2022 Feb 14, 2023	SELL	$19.7 - $35.71 $17,769 - $32,210	-902 Reduced 17.8%	4,166 $86,000
Q3 2022 Nov 14, 2022	BUY	$23.23 - $30.07 $905 - $1,172	39 Added 0.78%	5,068 $133,000
Q2 2022 Aug 12, 2022	BUY	$17.23 - $37.73 $18,522 - $40,559	1,075 Added 27.19%	5,029 $127,000
Q1 2022 May 16, 2022	SELL	$28.92 - $41.83 $6,507 - $9,411	-225 Reduced 5.38%	3,954 $125,000
Q4 2021 Feb 14, 2022	SELL	$31.38 - $48.47 $140,739 - $217,387	-4,485 Reduced 51.77%	4,179 $169,000
Q3 2021 Nov 15, 2021	SELL	$26.93 - $37.68 $12,037 - $16,842	-447 Reduced 4.91%	8,664 $302,000
Q2 2021 Aug 10, 2021	SELL	$22.75 - $35.77 $5,391 - $8,477	-237 Reduced 2.54%	9,111 $250,000
Q1 2021 May 17, 2021	BUY	$26.16 - $41.39 $4,185 - $6,622	160 Added 1.74%	9,348 $262,000
Q4 2020 Feb 12, 2021	SELL	$17.0 - $32.36 $32,079 - $61,063	-1,887 Reduced 17.04%	9,188 $239,000
Q3 2020 Nov 13, 2020	SELL	$17.14 - $25.47 $26,121 - $38,816	-1,524 Reduced 12.1%	11,075 $190,000
Q2 2020 Aug 05, 2020	BUY	$13.97 - $36.56 $176,008 - $460,619	12,599 New	12,599 $312,000
Q4 2018 Feb 05, 2019	SELL	$9.74 - $14.5 $279,236 - $415,700	-28,669 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$10.88 - $14.95 $229,187 - $314,921	-21,065 Reduced 42.36%	28,669 $400,000
Q2 2018 Aug 10, 2018	BUY	$12.24 - $17.05 $608,744 - $847,964	49,734 New	49,734 $609,000

Others Institutions Holding RCUS

# of Institutions

201

Shares Held

51.7M

Call Options Held

236K

Put Options Held

141K

View Full List

About Arcus Biosciences, Inc.

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.16B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

More about RCUS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtus ETF Advisers LLC with notifications on news.

Account

Virtus ETF Advisers LLC Arcus Biosciences, Inc. Transaction History